Try our Investor Tool
Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Try our Investor Tool
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Basilea Pharmaceutica AG
Clear Filter
Search
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
»
Date / Time
Source
Company
Sector
Market Cap
Announcement
07Jan20 09:48
EQS
Basilea Pharmaceutica AG
Health
597.2m
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23Apr19 11:27
EQS
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05
EQS
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18
EQS
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37
EQS
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17Aug18 09:15
EQS
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14Aug18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13Aug18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports on first Cresemba® approval in MENA region
09Aug18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19Jul18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16Jul18 10:35
EQS
Basilea Pharmaceutica AG
Health
597.2m
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26Jun18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05Jun18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15May18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04May18 10:44
EQS
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27Apr18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20Apr18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18Apr18 17:06
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18Apr18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17Apr18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09Apr18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19Mar18 11:10
EQS
Basilea Pharmaceutica AG
Health
597.2m
Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06Mar18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01Mar18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea names Adesh Kaul as new member of its Management Committee
27Feb18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports significantly improved financial results in 2017
23Feb18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21Feb18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10Jan18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03Jan18 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21Dec17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01Dec17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02Nov17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports on commercial progress of antifungal Cresemba® in Europe
31Oct17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23Oct17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11Oct17 13:17
EQS
Basilea Pharmaceutica AG
Health
597.2m
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28Sep17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12Sep17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10Aug17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20Jul17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14Jun17 18:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14Jun17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13Jun17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12Jun17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06Jun17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02Jun17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea names new member of its Extended Management Committee
27Apr17 17:32
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21Apr17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06Apr17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27Feb17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20Feb17 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports solid 2016 results and expects to double product sales in 2017
29Dec16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea names new member of its Extended Management Committee
02Dec16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15Nov16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea's antifungal Cresemba® (isavuconazole) launched in France
20Sep16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15Sep16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13Sep16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06Sep16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17Aug16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15Aug16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27Jun16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09Jun16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21Apr16 17:30
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20Apr16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15Apr16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15Mar16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea issues agenda for Annual General Meeting of Shareholders
09Mar16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04Mar16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03Mar16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29Feb16 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21Jan16 20:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29Dec15 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28Dec15 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea provides clinical program updates
18Dec15 17:42
GNW
Basilea Pharmaceutica AG
Health
597.2m
Final allocations of Basilea CHF 200 million senior convertible bonds
09Dec15 17:36
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea successfully places CHF 200 million senior convertible bonds
09Dec15 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea launches a senior convertible bond issue
05Nov15 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23Oct15 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces that European Commission maintained isavuconazole's orphan drug status
16Oct15 19:43
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces filing of registration statement for a proposed offering in the United States
16Oct15 15:48
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15Oct15 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12Oct15 06:15
GNW
Basilea Pharmaceutica AG
Health
597.2m
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
«
1
»
Date / Time
Source
Company
% Chg
07Jan20 09:48
EQS
Basilea Pharmaceutica AG
0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23Apr19 11:27
EQS
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05
EQS
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18
EQS
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37
EQS
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17Aug18 09:15
EQS
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14Aug18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13Aug18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports on first Cresemba® approval in MENA region
09Aug18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19Jul18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16Jul18 10:35
EQS
Basilea Pharmaceutica AG
0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26Jun18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05Jun18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15May18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04May18 10:44
EQS
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27Apr18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20Apr18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18Apr18 17:06
GNW
Basilea Pharmaceutica AG
0.00%
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18Apr18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17Apr18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09Apr18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19Mar18 11:10
EQS
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06Mar18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01Mar18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea names Adesh Kaul as new member of its Management Committee
27Feb18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports significantly improved financial results in 2017
23Feb18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21Feb18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10Jan18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03Jan18 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21Dec17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01Dec17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02Nov17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports on commercial progress of antifungal Cresemba® in Europe
31Oct17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23Oct17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11Oct17 13:17
EQS
Basilea Pharmaceutica AG
0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28Sep17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12Sep17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10Aug17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20Jul17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14Jun17 18:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14Jun17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13Jun17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12Jun17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06Jun17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02Jun17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea names new member of its Extended Management Committee
27Apr17 17:32
GNW
Basilea Pharmaceutica AG
0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21Apr17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06Apr17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27Feb17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20Feb17 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports solid 2016 results and expects to double product sales in 2017
29Dec16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea names new member of its Extended Management Committee
02Dec16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15Nov16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea's antifungal Cresemba® (isavuconazole) launched in France
20Sep16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15Sep16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13Sep16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06Sep16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17Aug16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15Aug16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27Jun16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09Jun16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21Apr16 17:30
GNW
Basilea Pharmaceutica AG
0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20Apr16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15Apr16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15Mar16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea issues agenda for Annual General Meeting of Shareholders
09Mar16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04Mar16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03Mar16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29Feb16 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21Jan16 20:15
GNW
Basilea Pharmaceutica AG
0.00%
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29Dec15 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28Dec15 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea provides clinical program updates
18Dec15 17:42
GNW
Basilea Pharmaceutica AG
0.00%
Final allocations of Basilea CHF 200 million senior convertible bonds
09Dec15 17:36
GNW
Basilea Pharmaceutica AG
0.00%
Basilea successfully places CHF 200 million senior convertible bonds
09Dec15 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea launches a senior convertible bond issue
05Nov15 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23Oct15 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces that European Commission maintained isavuconazole's orphan drug status
16Oct15 19:43
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces filing of registration statement for a proposed offering in the United States
16Oct15 15:48
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15Oct15 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12Oct15 06:15
GNW
Basilea Pharmaceutica AG
0.00%
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
«
1
»
Date / Time
Company
% Chg
07Jan20 09:48
Basilea Pharmaceutica AG
0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23Apr19 11:27
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17Aug18 09:15
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14Aug18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13Aug18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports on first Cresemba® approval in MENA region
09Aug18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19Jul18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16Jul18 10:35
Basilea Pharmaceutica AG
0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26Jun18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05Jun18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15May18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04May18 10:44
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27Apr18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20Apr18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18Apr18 17:06
Basilea Pharmaceutica AG
0.00%
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18Apr18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17Apr18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09Apr18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19Mar18 11:10
Basilea Pharmaceutica AG
0.00%
Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06Mar18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01Mar18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea names Adesh Kaul as new member of its Management Committee
27Feb18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports significantly improved financial results in 2017
23Feb18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21Feb18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10Jan18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03Jan18 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21Dec17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01Dec17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02Nov17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports on commercial progress of antifungal Cresemba® in Europe
31Oct17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23Oct17 06:15
Basilea Pharmaceutica AG
0.00%
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11Oct17 13:17
Basilea Pharmaceutica AG
0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28Sep17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12Sep17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10Aug17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20Jul17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14Jun17 18:15
Basilea Pharmaceutica AG
0.00%
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14Jun17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13Jun17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12Jun17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06Jun17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02Jun17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea names new member of its Extended Management Committee
27Apr17 17:32
Basilea Pharmaceutica AG
0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21Apr17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06Apr17 06:15
Basilea Pharmaceutica AG
0.00%
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27Feb17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20Feb17 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports solid 2016 results and expects to double product sales in 2017
29Dec16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea names new member of its Extended Management Committee
02Dec16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15Nov16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea's antifungal Cresemba® (isavuconazole) launched in France
20Sep16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15Sep16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13Sep16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06Sep16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17Aug16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15Aug16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27Jun16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09Jun16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21Apr16 17:30
Basilea Pharmaceutica AG
0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20Apr16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15Apr16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15Mar16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea issues agenda for Annual General Meeting of Shareholders
09Mar16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04Mar16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03Mar16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29Feb16 06:15
Basilea Pharmaceutica AG
0.00%
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21Jan16 20:15
Basilea Pharmaceutica AG
0.00%
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29Dec15 06:15
Basilea Pharmaceutica AG
0.00%
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28Dec15 06:15
Basilea Pharmaceutica AG
0.00%
Basilea provides clinical program updates
18Dec15 17:42
Basilea Pharmaceutica AG
0.00%
Final allocations of Basilea CHF 200 million senior convertible bonds
09Dec15 17:36
Basilea Pharmaceutica AG
0.00%
Basilea successfully places CHF 200 million senior convertible bonds
09Dec15 06:15
Basilea Pharmaceutica AG
0.00%
Basilea launches a senior convertible bond issue
05Nov15 06:15
Basilea Pharmaceutica AG
0.00%
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23Oct15 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces that European Commission maintained isavuconazole's orphan drug status
16Oct15 19:43
Basilea Pharmaceutica AG
0.00%
Basilea announces filing of registration statement for a proposed offering in the United States
16Oct15 15:48
Basilea Pharmaceutica AG
0.00%
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15Oct15 06:15
Basilea Pharmaceutica AG
0.00%
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12Oct15 06:15
Basilea Pharmaceutica AG
0.00%
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
«
1
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Blogs
Academy
Insights
News
Research Tree
The Naked Fund Manager
Ideas & Picks
Ideas Hub
Stock Pick League
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Aic Sectors
Asia Pacific
Asia Pacific Equity Income
Asia Pacific Smaller Companies
Biotechnology & Healthcare
China / Greater China
Commodities & Natural Resources
Country Specialist
Debt - Loans & Bonds
Environmental
Europe
European Smaller Companies
Farmland & Forestry
Flexible Investment
Global
Global Emerging Markets
Global Equity Income
Global Smaller Companies
Growth Capital
India
Infrastructure
Japan
Japanese Smaller Companies
Latin America
Liquidity Funds
North America
North American Smaller Companies
Private Equity
Property - Europe
Property - Rest of World
Property - UK Commercial
Property - UK Residential
Property Securities
Renewable Energy Infrastructure
UK All Companies
UK Equity & Bond Income
UK Equity Income
UK Smaller Companies
VCT AIM Quoted
VCT Generalist
VCT Generalist Pre Qualifying
VCT Specialist: Environmental
VCT Specialist: Environmental Pre Qualifying
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
Align Research
BNP Paribas Exane - Sponsored Research
BRR Media
Calvine Partners
Capital Access Group
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
goetzpartners securities Limited
Hardman & Co
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Radnor Capital Partners
Research Tree
SEAL Advisors Ltd
ShareSoc
Trinity Delta
Yellowstone Advisory
High Net Worth Offering
Fox-Davies Capital
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cenkos Securities
Couloir Capital
Dowgate Capital
finnCap
First Berlin
First Sentinel
Hannam & Partners
Hybridan
Liberum
Longspur Research
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
The Life Sciences Division
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane
BNP Paribas Exane - Sponsored Research
BRR Media
Bryan, Garnier & Co
Calderwood Capital
Calvine Partners
Canaccord Genuity
Capital Access Group
Cenkos Securities
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
finnCap
First Berlin
First Sentinel
Five Minute Pitch TV
goetzpartners securities Limited
Hannam & Partners
Hardman & Co
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Research
Magnitogorsk Iron and steel works
Mello Events
Northland Capital Partners
Numis
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Radnor Capital Partners
Research Tree
SEAL Advisors Ltd
Shard Capital
ShareSoc
Shore Capital
SI Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
The Life Sciences Division
Trinity Delta
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Video/Audio Interviews
BRR Media
Capital Access Group
Couloir Capital
Edison
Equity Development
Five Minute Pitch TV
piworld.co.uk
Proactive
QuotedData
RaaS - Research as a Service
Research Tree
Yellowstone Advisory
Event Providers
Capital Access Group
Cenkos Securities
Couloir Capital
Edison
Equity Development
Hardman & Co
InterAxS Global
Kepler | Trust Intelligence
London Stock Exchange
Mello Events
piworld.co.uk
QuotedData
Research Tree
ShareSoc
VSA Capital
Yellowstone Advisory
Contact
Sign Up
Sign In
Share: